Sign up Australia
Proactive Investors - Run By Investors For Investors

Immuron gets ready to begin clinical trial of new drug candidate

CDI causes an estimated annual economic cost of more than US$10 billion.
Immuron gets ready to begin clinical trial of new drug candidate
Phase 1/2 clinical trial of IMM-529 to start by the end of Q2 2017

Immuron (ASX:IMC) has successfully manufactured trial supplies of its clinical candidate IMM-529, an oral immunotherapeutic targeting the prevention of clostridium difficile Infection (CDI).

CDI results from disruption of normal, healthy bacteria in the colon, often as a result of antibiotics.

IMM-529 is a biological product which is intended to prevent and treat CDI without destroying the microbiome like antibiotic treatments, allowing the microbiome to return to a healthy state.

The antibodies survive transit through the stomach and remain functional in the large intestine.

IMM-529 was manufactured by the Commonwealth Scientific and Industrial Research Organisation (CSIRO) Separations Science team and Pharmaceutical Packaging Professionals.

Human safety and efficacy studies (Phase 1/2 clinical trial) of IMM-529 will start by the end of Q2 2017, and will aim to build on positive pre-clinical results.

These results were reported from a series of proof-of-concept efficacy studies completed by Dr. Dena Lyras and her research team at the Monash University in Melbourne.

CDI has become a major-medical problem causing an estimated annual economic cost of more than US$10 billion globally.

The problem is especially acute in hospitals and in long-term in-patient care facilities.

An estimated 29,000 patients die each year from CDI in the U.S. alone. Recurrent CDI affects circa 100,000 people in the U.S. annually.

Immuron’s share price has more than doubled since the start of 2017, last trading at $0.55.

View full IMC profile View Profile

Immuron Ltd Timeline

Newswire
June 08 2017
Newswire
May 30 2017
Newswire
May 27 2016

Related Articles

biotech2.jpg
August 18 2017
The company operates a hybrid model, which means its revenues come from providing antibody research and engineering services and creating drug conjugates (targeted treatments for diseases such as cancer). It also manufactures antibodies and proteins for clinical studies
cancer cells
December 15 2017
The AIM-listed group, whose focus is cancer and autoimmune diseases, licensed its SRA737 to US firm Sierra Oncology just over a year ago
blood cells
October 24 2017
“We are delighted to report positive results from the Phase II study. We believe PeproStat is a first-in-class product which could enter the large and growing haemostat market as early as 2020.”

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use